| (Values in U.S. Thousands) | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 |
| Sales | 3,765,700 | 4,144,900 | 3,697,600 | 3,745,800 | 3,572,300 |
| Sales Growth | -9.15% | +12.10% | -1.29% | +4.86% | -6.14% |
| Net Income | 550,600 | 3,105,400 | 550,800 | 240,300 | 375,000 |
| Net Income Growth | -82.27% | +463.80% | +129.21% | -35.92% | -18.00% |
Shire Plc Ads (SHPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)
Fiscal Year End Date: 12/31